Airway Remodeling in Chronic Obstructive Pulmonary Disease and Asthma: the Role of Matrix Metalloproteinase-9

Archivum Immunologiae et Therapiae Experimentalis

Volumn 64, Issue 1, 2016, Pages 47-55

  Grzela, Katarzyna ^a   Litwiniuk, Malgorzata ^a,b   Zagorska, Wioletta ^a   Grzela, Tomasz ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b Potgraduate School of Molecular Medicine   (Poland)

Author keywords

Asthma; Chronic obstructive pulmonary disease; COPD; MMP 9; Remodeling

Indexed keywords

AE 941; ALPHA 1 ANTITRYPSIN; BATIMASTAT; CERIVASTATIN; COLLAGENASE 3; GELATINASE B; ILOMASTAT; INTERLEUKIN 1; MARIMASTAT; SIMVASTATIN; TETRACYCLINE DERIVATIVE; VASCULOTROPIN;

AIRWAY REMODELING; AMINO ACID SUBSTITUTION; ANGIOGENESIS; ASTHMA; BRONCHOCONSTRICTION; CHRONIC INFLAMMATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORRELATION ANALYSIS; ELECTROPHORESIS; ENZYME INHIBITION; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GENETIC TRANSCRIPTION; HUMAN; INDEL MUTATION; LUNG LAVAGE; NEUTROPHIL COUNT; NONHUMAN; PROMOTER REGION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; ANIMAL; GENE EXPRESSION PROFILING; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; INFLAMMATION; METABOLISM;

AIRWAY REMODELING; ANIMALS; ASTHMA; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATION; MATRIX METALLOPROTEINASE 9; POLYMORPHISM, GENETIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84954400585     PISSN: 0004069X     EISSN: 16614917     Source Type: Journal    
DOI: 10.1007/s00005-015-0345-y     Document Type: Review

References (89)

1. Abel M, Vliagoftis H (2008) Mast cell-fibroblast interactions induce matrix metalloproteinase-9 release from fibroblasts: role for IgE-mediated mast cell activation. J Immunol 180:3543–3550
2. Atkinson JJ, Senior RM (2003) Matrix metalloproteinase-9 in lung remodeling. Am J Respir Cell Mol Biol 28:12–24
3. Barbato A, Turato G, Baraldo S et al (2003) Airway inflammation in childhood asthma. Am J Respir Crit Care Med 168:798–803
4. Beckett PA, Howarth PH (2003) Pharmacotherapy and airway inflammation and remodeling. Thorax 58:163–174
5. Belleguic C, Corbel M, Germain N et al (2002) Increased release of matrix metalloproteinase-9 in the plasma of acute severe asthmatic patients. Clin Exp Allergy 32:217–223
6. Birkedal-Hansen H, Moore WG, Bodden MK et al (1993) Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 4:197–250
7. Bisgaard H, Hermansen MN, Loland L et al (2006) Intermittent inhaled corticosteroids in infants with episodic wheezing. N Engl J Med 354:1998–2005
8. Brajer B, Batura-Gabryel H, Nowicka A et al (2008) Concentration of matrix metalloproteinase-9 in serum of patients with chronic obstructive pulmonary disease and a degree of airway obstruction and disease progression. J Physiol Pharmacol 59(Suppl 6):145–152
9. Brand K, Ahout I, de Groot R et al (2012) Use of MMP-8 and MMP-9 to assess disease severity in children with viral lower respiratory tract infections. J Med Virol 84:1471–1480
10. Broide DH (2008) Immunologic and inflammatory mechanisms that drive asthma progression to remodeling. J Allergy Clin Immunol 121:560–572
11. Buist AS, McBurnie MA, Vollmer WM et al (2007) International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study. Lancet 370:741–750
12. Cataldo DD, Bettiol J, Noel A et al (2002) Matrix metalloproteinase-9, but not tissue inhibitor of matrix metalloproteinase-1, increases in the sputum from allergic asthmatic patients after allergen challenge. Chest 122:1553–1559
13. Chakraborti S, Mandal M, Das S et al (2003) Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem 253:269–285
14. Churg A, Zhou S, Preobrazhenska O et al (2009) Expression of profibrotic mediators in small airways versus parenchyma after cigarette smoke exposure. Am J Respir Cell Mol Biol 40:268–276
15. Collier IE, Bruns GA, Goldberg GI et al (1991) On the structure and chromosome location of the 72- and 92-kDa human type IV collagenase genes. Genomics 9:429–434
16. Crosby LM, Waters CM (2010) Epithelial repair mechanisms in the lung. Am J Physiol Lung Cell Mol Physiol 298:L715–L731
17. Culpitt SV, Rogers DF, Traves SL et al (2005) Sputum matrix metalloproteases: comparison between chronic obstructive pulmonary disease and asthma. Respir Med 99:703–710
18. Curci JA, Petrinec D, Liao S et al (1998) Pharmacologic suppression of experimental abdominal aortic aneurysms: a comparison of doxycycline and four chemically modified tetracyclines. J Vasc Surg 28:1082–1093
19. Decramer M, Janssens W, Miravitlles M (2012) Chronic obstructive pulmonary disease. Lancet 379:1341–1351
20. Ding R, McGuinness CL, Burnand KG et al (2005) Matrix metalloproteinases in the neurysm wall of patients treated with low-dose doxycycline. Vascular 13:290–297
21. Ding QL, Sun SF, Cao C et al (2012) Association between angiotensin-converting enzyme I/D polymorphism and asthma risk: a meta-analysis involving 11,897 subjects. J Asthma 49:557–562
22. Engsig MT, Chen TH, Vu A et al (2000) Matrix metalloproteinase 9 and vascular endothelial growth factor are essential for osteoclast recruitment into developing long bones. J Cell Biol 151:879–890
23. Erlewyn-Lajeunesse M, Hunt L, Pohunek P et al (2008) Bronchoalveolar lavage MMP-9 and TIMP-1 in preschool wheezers and their relationship to persistent wheeze. Pediatr Res 64:194–199
24. Fanjul-Fernández M, Folgueras AR, Cabrera S et al (2010) Matrix metalloproteinases: evolution, gene regulation and functional analysis in mouse models. Biochim Biophys Acta 1803:3–19
25. Fujiwara Y, Shiraya S, Miyake T et al (2008) Inhibition of experimental abdominal aortic aneurysm in a rat model by an angiotensin receptor blocker, valsartan. Int J Mol Med 22:703–708
26. Gagliardo R, La Grutta S, Chanez P et al (2009) Non-invasive markers of airway inflammation and remodeling in childhood asthma. Pediatr Allergy Immunol 20:780–790
27. Ganter K, Deichmann KA, Heinzmann A (2005) Study of polymorphisms within matrix metalloproteinase 9 with bronchial asthma. Int J Immunogenet 32:233–236
28. Global Initiative for Chronic Obstructive Lung Disease (2010) Global strategy for the diagnosis, management, and prevention of COPD: updated 2010. http://www.goldcopd.org/uploads/users/files/GOLDReport_April112011.pdf
29. Grainge CL, Lau LC, Ward JA et al (2011) Effect of bronchoconstriction on airway remodeling in asthma. N Engl J Med 364:2006–2015
30. Grzela T, Bialoszewska A (2010) Genetic risk factors of chronic venous leg ulceration: can molecular screening aid in the prevention of chronic venous insufficiency complications? Mol Med Rep 3:205–211
31. Grzela T, Bikowska B, Litwiniuk M (2011) Matrix metalloproteinases in aortic aneurysm—executors or executioners? In: Grundmann RT (ed) Etiology, Pathogenesis and Pathophysiology of Aortic Aneurysms and Aneurysm Rupture. Intech Publ, Rijeka, pp 25–54
32. Grzela K, Zagorska W, Jankowska-Steifer E et al (2013) Chronic inflammation in the respiratory tract and ciliary dyskinesia. Centr Eur J Immunol 38:122–128
33. Grzela T, Niderla-Bielinska J, Litwiniuk M et al (2014) The direct inhibition of MMP-2 and MMP-9 by an enzyme alginogel: a possible mechanism of healing support for venous leg ulcers. J Wound Care 23:278–284
34. Grzela K, Zagorska W, Krejner A et al (2015) Prolonged treatment with inhaled corticosteroids does not normalize high activity of matrix metalloproteinase-9 in exhaled breath condensates of children with asthma. Arch Immunol Ther Exp 63:231–237
35. Hadler-Olsen E, Fadnes B, Sylte I et al (2011) Regulation of matrix metalloproteinase activity in health and disease. FEBS J 278:28–45
36. Hamilton LM, Puddicombe SM, Dearman RJ et al (2005) Altered protein tyrosine phosphorylation in asthmatic bronchial epithelium. Eur Respir J 25:978–985
37. Haswell LE, Hewitt K, Thorne D et al (2010) Cigarette smoke total particulate matter increases mucous secreting cell numbers in vitro: a potential model of goblet cell hyperplasia. Toxicol In Vitro 24:981–987
38. Holgate ST (2007) Epithelium dysfunction in asthma. J Allergy Clin Immunol 120:1233–1244
39. Holgate ST (2010) A brief history of asthma and its mechanisms to modern concepts of disease pathogenesis. Allergy Asthma Immunol Res 2:165–171
40. Holgate ST, Lackie PM, Davies DE et al (1999) The bronchial epithelium as a key regulator of airway inflammation and remodeling in asthma. Clin Exp Allergy 29(Suppl 2):90–95
41. Holla LI, VasÏku A, Stejskalova A et al (2000) Functional polymorphism in the gelatinase B gene and asthma. Allergy 55:900–901
42. Inoue H, Mashimo Y, Funamizu M et al (2012) Association of the MMP9 gene with childhood cedar pollen sensitization and pollinosis. J Human Genet 57:176–183
43. James A (2005) Airway remodeling in asthma. Curr Opin Pulm Med 11:1–6
44. Jeffery PK (2001a) Remodeling in asthma and chronic obstructive lung disease. Am J Respir Crit Care Med 164(10 Pt):S28–S38
45. Jeffery PK (2001b) The roles of leukotrienes and the effects of leukotriene receptor antagonists in the inflammatory response and remodeling of allergic asthma. Clin Exp Allergy Rev 1:148–153
46. Kalluri R, Neilson EG (2003) Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 112:1776–1784
47. Kaparianos A, Argyropoulou E (2011) Local renin–angiotensin II systems, angiotensin-converting enzyme and its homologue ACE2: their potential role in the pathogenesis of chronic obstructive pulmonary diseases, pulmonary hypertension and acute respiratory distress syndrome. Curr Med Chem 18:3506–3515
48. Kimata M, Ishizaki M, Tanaka H et al (2006) Production of matrix metalloproteinases in human cultured mast cells: involvement of protein kinase C-mitogen activated protein kinase kinase-extracellular signal-regulated kinase pathway. Allergol Int 55:67–76
49. Klein T, Bischoff R (2011) Physiology and pathophysiology of matrix metalloproteases. Amino Acids 41:271–290
50. Kong MY, Gaggar A, Li Y et al (2009) Matrix metalloproteinase activity in pediatric acute lung injury. Int J Med Sci 6:9–17
51. Kranenburg AR, Willems-Widyastuti A, Moori WJ et al (2006) Enhanced bronchial expression of extracellular matrix proteins in chronic obstructive pulmonary disease. Am J Clin Pathol 126:725–735
52. Lapperre TS, Sont JK, van Schadewijk A et al (2007) Smoking cessation and bronchial epithelial remodelling in COPD: a cross-sectional study. Respir Res 8:85
53. Lee YC, Lee HB, Rhee YK et al (2001) The involvement of matrix metalloproteinase-9 in airway inflammation of patients with acute asthma. Clin Exp Allergy 31:1623–1630
54. Lee SY, Paik SY, Chung SM (2005) Neovastat (AE-941) inhibits the airway inflammation and hyperresponsiveness in a murine model of asthma. J Microbiol 43:11–16
55. Lee SY, Kim MJ, Kang HG et al (2010) Polymorphisms in matrix metalloproteinase-1, -9 and -12 genes and the risk of chronic obstructive pulmonary disease in a Korean population. Respiration 80:133–138
56. Lemjabbar H, Gosset P, Lamblin C et al (1999) Contribution of 92 kDa gelatinase/type IV collagenase in bronchial inflammation during status asthmaticus. Am J Respir Crit Care Med 159:1298–1307
57. Liang KC, Lee CW, Lin WN et al (2007) Interleukin-1beta induces MMP-9 expression via p42/p44 MAPK, p38 MAPK, JNK, and nuclear factor-kappaB signaling pathways in human tracheal smooth muscle cells. J Cell Physiol 211:759–770
58. Lim DH, Cho JY, Miller M et al (2006) Reduced peribronchial fibrosis in allergen-challenged MMP-9-deficient mice. Am J Physiol Lung Cell Mol Physiol 291:L265–L271
59. Litwiniuk M, Bikowska B, Niderla-Bielińska J et al (2012) Potential role of metalloproteinase inhibitors from radiation-sterilized amnion dressings in the healing of venous leg ulcers. Mol Med Rep 6:723–728
60. Liu ZX, Zhou SD, Shapiro JM et al (2000) The serpin alpha1-proteinase inhibitor is a critical substrate for gelatinase B/MMP-9 in vivo. Cell 102:647–655
61. Lowrey GE, Henderson N, Blakey JD et al (2008) MMP-9 protein level does not reflect overall MMP activity in the airways of patients with COPD. Respir Med 102:845–851
62. Masoli M, Fabian D, Holt S et al (2004) The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 59:469–478
63. Mauad T, Bel EH, Sterk PJ (2007) Asthma therapy and airway remodeling. J Allergy Clin Immunol 120:997–1009
64. McMillan SJ, Xanthou G, Lloyd CM (2005) Manipulation of allergen-induced airway remodeling by treatment with anti-TGF-beta antibody: effect of the Smad signaling pathway. J Immunol 174:5774–5780
65. Medley TL, Cole TJ, Dart AM et al (2004) Matrix metalloproteinase-9 genotype influences large artery stiffness through effects on aortic gene and protein expression. Arterioscler Thromb Vasc Biol 24:1479–1484
66. Nagashima H, Aoka Y, Sakomura Y et al (2002) A 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, cerivastatin, suppresses production of matrix metalloproteinase-9 in human abdominal aortic aneurysm wall. J Vasc Surg 36:158–163
67. Panettieri RA Jr, Kotlikoff MI, Gerthoffer WT et al (2008) Airway smooth muscle in bronchial tone, inflammation, and remodeling: basic knowledge to clinical relevance. Am J Respir Crit Care Med 177:248–252
68. Pascual RM, Peters SP (2005) Airway remodeling contributes to the progressive loss of lung function in asthma: an overview. J Allergy Clin Immunol 116:477–486
69. Patterson BC, Sang QA (1997) Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9). J Biol Chem 272:28823–28825
70. Pinto LA, Depner M, Klopp N et al (2010) MMP-9 gene variants increase the risk for non-atopic asthma in children. Respir Res 11:23
71. Rahman I, Adcock IM (2006) Oxidative stress and redox regulation of lung inflammation in COPD. Eur Respir J 28:219–242
72. Salazar LM, Herrera AM (2011) Fibrotic response of tissue remodeling in COPD. Lung 189:101–109
73. Salib RJ, Howarth PH (2003) Remodelling of the upper airways in allergic rhinitis: is it a feature of the disease? Clin Exp Allergy 33:1629–1633
74. Sampsonas F, Kaparianos A, Lykouras D et al (2007) DNA sequence variations of metalloproteinases: their role in asthma and COPD. Postgrad Med J 83:244–250
75. Sears MR (2014) Trends in the prevalence of asthma. Chest 145:219–225
76. Sethi S, Mahler DA, Marcus P et al (2012) Inflammation in COPD: implications for management. Am J Med 125:1162–1170
77. Shono T, Motoyama M, Tatsumi K et al (1998) A new synthetic matrix metalloproteinase inhibitor modulates both angiogenesis and urokinase type plasminogen activator activity. Angiogenesis 2:319–329
78. Shrikrishna D, Astin R, Kemp PR et al (2012) Renin–angiotensin system blockade: a novel therapeutic approach in chronic obstructive pulmonary disease. Clin Sci 123:487–498
79. Sohal SS, Soltani A, Reid D et al (2014) A randomized controlled trial of inhaled corticosteroids (ICS) on markers of epithelial–mesenchymal transition (EMT) in large airway samples in COPD: an exploratory proof of concept study. Int J Chron Obstruct Pulmon Dis 9:533–542
80. Tesfaigzi Y, Myers OB, Stidley CA et al (2006) Genotypes in matrix metalloproteinase 9 are a risk factor for COPD. Int J Chron Obstruct Pulmon Dis 1:267–278
81. Todorova L, Gürcan E, Westergren-Thorsson G et al (2009) Budesonide/formoterol effects on metalloproteolytic balance in TGF-β-activated human lung fibroblasts. Respir Med 103:1755–1763
82. Ward C, Walters H (2005) Airway wall remodeling: the influence of corticosteroids. Curr Opin Allergy Clin Immunol 5:43–48
83. Ward C, Pais M, Bish R et al (2002) Airway inflammation, basement membrane thickening and bronchial hyperresponsiveness in asthma. Thorax 57:309–316
84. Westergren-Thorsson G, Larsen K, Nihlberg K et al (2010) Pathological airway remodeling in inflammation. Clin Respir J 4(Suppl 1):1–8
85. Wynn A (2007) Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest 117:524–529
86. Xie S, Sukkar MB, Issa R et al (2007) Mechanisms of induction of airway smooth muscle hyperplasia by transforming growth factor-β. Am J Physiol Lung Cell Mol Physiol 293:L245–L253
87. Ye S (2000) Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases. Matrix Biol 19:623–629
88. Ye S (2006) Influence of matrix metalloproteinase genotype on cardiovascular disease susceptibility and outcome. Cardiovasc Res 69:636–645
89. Zhang B, Ye S, Herrmann SM et al (1999) Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 99:1788–1794